Funny and late: targeting currents governing heart rate in atrial fibrillation.
作者信息
Daniels James D, Hill Joseph A
机构信息
Department of Internal Medicine (Cardiology), UT Southwestern Medical Center, Dallas, Texas, USA.
出版信息
J Cardiovasc Electrophysiol. 2015 Mar;26(3):336-8. doi: 10.1111/jce.12597. Epub 2015 Jan 15.
Abstract
摘要
相似文献
1
Funny and late: targeting currents governing heart rate in atrial fibrillation.有趣且滞后：针对心房颤动中控制心率的电流
J Cardiovasc Electrophysiol. 2015 Mar;26(3):336-8. doi: 10.1111/jce.12597. Epub 2015 Jan 15.
2
Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.伊伐布雷定与雷诺嗪联合应用可降低心房颤动时的心室率。
J Cardiovasc Electrophysiol. 2015 Mar;26(3):329-35. doi: 10.1111/jce.12569. Epub 2014 Dec 5.
3
Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance.在心房颤动患者中，伊伐布雷定与β受体阻滞剂联用：对心率和运动耐量的影响。
Int J Cardiol. 2016 Jan 1;202:73-4. doi: 10.1016/j.ijcard.2015.08.207. Epub 2015 Aug 31.
4
Ivabradine for rate control in atrial fibrillation.
Int J Cardiol. 2015 Jan 20;179:27-8. doi: 10.1016/j.ijcard.2014.10.062. Epub 2014 Oct 22.
5
Need for further studies on ivabradine in patients with persistent atrial fibrillation.对持续性心房颤动患者使用伊伐布雷定需进一步研究。
Int J Cardiol. 2016 Nov 15;223:915-916. doi: 10.1016/j.ijcard.2016.08.329. Epub 2016 Aug 23.
6
Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation.伊伐布雷定可降低非阵发性心房颤动患者的心室率。
Int J Cardiol. 2016 Dec 1;224:252-255. doi: 10.1016/j.ijcard.2016.09.044. Epub 2016 Sep 16.
7
Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.急性伊伐布雷定治疗可降低心率，且不增加犬类房颤的诱发率，无论其潜在的迷走神经活动如何。
Heart Vessels. 2017 Apr;32(4):484-494. doi: 10.1007/s00380-016-0922-y. Epub 2016 Nov 14.
8
Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?伊伐布雷定对心房颤动的有效抑制作用：一种已上市药物的新靶点？
Int J Cardiol. 2017 Jun 1;236:237-243. doi: 10.1016/j.ijcard.2017.02.055. Epub 2017 Feb 27.
9
In vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of I plus I inhibitor ranolazine using the halothane-anesthetized dogs.在氟烷麻醉犬中评价 I+I 型抑制剂雷诺嗪抗房颤作用和药理学安全性。
Heart Vessels. 2021 Jul;36(7):1088-1097. doi: 10.1007/s00380-021-01830-1. Epub 2021 Mar 24.
10
Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.多非利特与雷诺嗪联合应用于马急性诱导心房颤动模型的抗心律失常作用。
J Cardiovasc Pharmacol. 2018 Jan;71(1):26-35. doi: 10.1097/FJC.0000000000000541.
本文引用的文献
1
Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.地高辛与成人房颤患者的死亡风险：ATRIA-CVRN研究
Circ Arrhythm Electrophysiol. 2015 Feb;8(1):49-58. doi: 10.1161/CIRCEP.114.002292. Epub 2014 Nov 20.
2
Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.伊伐布雷定与雷诺嗪联合应用可降低心房颤动时的心室率。
J Cardiovasc Electrophysiol. 2015 Mar;26(3):329-35. doi: 10.1111/jce.12569. Epub 2014 Dec 5.
3
Ivabradine in stable coronary artery disease without clinical heart failure.稳定性冠状动脉疾病且无临床心力衰竭的伊伐布雷定。
N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.
4
Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.雷诺嗪作为心房颤动一种有前景的治疗选择：电生理机制、实验证据及临床意义
Pacing Clin Electrophysiol. 2014 Oct;37(10):1412-20. doi: 10.1111/pace.12486. Epub 2014 Aug 19.
5
Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system.心房颤动药物治疗的趋势：来自退伍军人事务部医疗系统的数据。
Am Heart J. 2014 Jul;168(1):53-9.e1. doi: 10.1016/j.ahj.2014.03.024. Epub 2014 May 2.
6
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).依伐布雷定治疗严重慢性收缩性心力衰竭患者的疗效和安全性（来自 SHIFT 研究）。
Am J Cardiol. 2014 Feb 1;113(3):497-503. doi: 10.1016/j.amjcard.2013.10.033. Epub 2013 Nov 9.
7
Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.雷诺嗪对稳定型冠状动脉疾病症状患者的影响。系统评价和荟萃分析。
Int J Cardiol. 2013 Nov 15;169(4):262-70. doi: 10.1016/j.ijcard.2013.08.131. Epub 2013 Sep 7.
8
Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness.钙通道阻滞剂与β受体阻滞剂在无急性基础疾病的心房颤动患者中控制心室率的安全性和有效性。
Acad Emerg Med. 2013 Mar;20(3):222-30. doi: 10.1111/acem.12091.
9
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation.比较四种单药治疗方案对永久性心房颤动患者心室率及心律失常相关症状的影响。
Am J Cardiol. 2013 Jan 15;111(2):225-30. doi: 10.1016/j.amjcard.2012.09.020. Epub 2012 Oct 27.
10
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.小剂量雷诺嗪和决奈达隆联合应用对急性心肌缺血时的心房颤动和室性心律失常易感性具有强大的保护作用。
Heart Rhythm. 2013 Jan;10(1):121-7. doi: 10.1016/j.hrthm.2012.09.015. Epub 2012 Sep 14.
Zotero 插件